SEC Form 4 · accession 0001628280-26-042571
BECTON DICKINSON & CO · BDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael David Garrison
Officer — EVP & Pres Med.Essntl&BioPharm
Period of report
Jun 10, 2026
Accepted (ET)
Jun 11, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000010795
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 10, 2026 | S | 1,100 | $151.48 | D | 14,272 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.
Remarks
The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2026.